Theseus Pharmaceuticals Announces First Patient Treated with THE-630 in Phase 1/2 Study in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

CAMBRIDGE, Mass.: CAMBRIDGE, Mass., Jan. 10, 2022 /PRNewswire/ — Theseus Pharmaceuticals, Inc. (Theseus) (NASDAQ: THRX), a clinical stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the first patient has been treated in the Phase 1 portion of Theseus’ ongoing Phase 1/2 study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST).
Click here to view original post